血液系统恶性肿瘤的靶向治疗
摘要
社区卫生医疗服务需要解决的是患者的基本医疗问题,全科医生面临的大多是常见病、多发病或者是一些非常见疾病的初期处理。这是否意味着他们不需要学习、了解医学专科临床中的新知识、新进展呢?显然不是。一些临床诊断、治疗领域的新进展,虽然离基层社区医生实际应用较远,但不应该不知道。因为了解它们,不仅能更新、拓宽了自身的知识库,不落后于医学知识发展的步伐,而且能提高医生自身的素质,更多获得患者的信任,也就能更好地服务于患者。
出处
《中华全科医师杂志》
2007年第5期284-286,共3页
Chinese Journal of General Practitioners
参考文献11
-
1Lobuglio AF, Saleh MN. Monoclonal antibody therapy of cancer. Cfit Rev Oncol Hematol, 1992,13:271-282.
-
2Coucxmum MS, Crib Lopez AJ, White CA, et al. Treatment of patients with low B cell lymphoma with the combination of chemic anti CD20 monoclonal antibody and CHOP chemotherapy. Clin Oncol, 1999,17:268-276.
-
3Kaminski MS, Tuck M, Regan D, et al. High response rates and durable remissions in patients with previously untreated advanced stage follicular lymphoma treated with tositumomab and iodine 131 tositumomab ( Bexxar ). Blood ,2002,100 ( 1 ) 1:356-365.
-
4Kaminski M S. 131 I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 2005, 352:441-449.
-
5Kreitman RJ, Wilson WH, Bergeron K, et al. Effi-cacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapyresistant hairy-cell leukemia. N Engl J Med, 2001, 345: 241-247.
-
6陈波斌,林果为,陆华中,范华骅,郭荣,肖娟,高跞,高峰.抗bcr/abl mRNA特异性核酶作用于靶基因的细胞内外切割实验[J].复旦学报(医学版),2003,30(3):259-262. 被引量:3
-
7Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias. Clin Cancer Res, 2004, 10:3577-3555.
-
8Chen HX. Expanding the clinical development of bevacizumab. Oncologist ,2004,9 Suppl 1:27-35.
-
9Fanale MA. Monoclonal antibodies in the treatment of nonHodgkin' s lymphoma. Drugs, 2007,67:333-350.
-
10Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol,2001,8 :739.
二级参考文献6
-
1Frank DK, Pace NR, Ribonuclease P. Unity and diversity in a tRNA processing ribozyme. A nnu Rev Biochem , 1998;67:153
-
2Doherty RA, Doudna JA. Ribozyme structure and mechanisms. Annu Rev Biochem, 2000,69: 597
-
3Cobaleda C, Sanchez-Garcia I. RNase P: from biological function to biotechnological applications. Trends in Biotechnology, 2001,19: 401
-
4Kraus G, Geffin R, Spruill G, et al. Cross-clade inhibition of HIV-1replication and cytopathology by using RNase P-associated external guide sequences. PNAS, 2002,99: 3406
-
5Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol , 1995,15: 5531
-
6陈波斌,林果为,郭荣,陆华中,范华骅,肖娟,高跞,高峰.抗慢性粒细胞性白血病bcr/abl mRNA真核表达载体的构建[J].复旦学报(医学版),2003,30(1):1-3. 被引量:3
-
1沈周俊,何竑超.降低前列腺特异性抗原预警值在前列腺癌早期诊断中的应用[J].中华泌尿外科杂志,2009,30(3):214-215. 被引量:1
-
2王锡山.社区医生早期识别结直肠癌的方法[J].中国社区医师,2013(45):20-21.
-
3谭小秋.不良情绪也可以导致癌症吗?[J].中国健康月刊,2004(11):97-97.
-
4张卫平,戴继舫.前列腺癌PSA筛查:基于流行病学的证据[J].公共卫生与预防医学,2014,25(6):74-76. 被引量:11
-
5姜中蓉.眼内视网膜母细胞瘤初期处理中的化学减容法[J].美国医学会眼科杂志(中文版),1997,9(3):146-153.
-
6杜亚文,张家亮.吗啡控释片不同剂量治疗癌痛156例分析及护理对策[J].中国现代医药杂志,2009,11(3):114-115. 被引量:1
-
7林擎天.结直肠癌肝转移的诊治[J].上海医药,2012,33(20):12-16.
-
8有前途的新的放射疗法[J].中国医刊,2005,40(1):61-61.
-
9毛丽莉.癌性疼痛的护理进展[J].中国医学文摘(内科学),2005,26(4):522-523. 被引量:10
-
10左玲,邓建春,邓亭月.在社区卫生应用TCT联合高危型HPV检测筛查宫颈癌的可行性研究[J].吉林医学,2016,37(6):1412-1413. 被引量:5